Proteasome inhibitors recent progress and future directions

Proteasome inhibitors recent progress and future directions Book Chapter

Wehenkel, M, Ho, YK, Kim, KB. (2009). Proteasome inhibitors recent progress and future directions . 99-119. 10.1007/978-0-387-69147-3_7

The proteasome continues to be an attractive target for cancer drug discovery and was validated as such by the successful development of bortezomib. Despite its remarkable efficacy, concerns regarding side effects and drug resistance limit the widespread application of bortezomib. Thus, there has been a heightened interest in the development of a new class of proteasome inhibitors. In this chapter, we discuss recent efforts towards the development of proteasome inhibitors. In addition, we discuss a novel class of compounds targeting an alternative proteasome, the immunoproteasome. © 2009 Springer-Verlag New York.